1. Home
  2. MHH vs CRDF Comparison

MHH vs CRDF Comparison

Compare MHH & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mastech Digital Inc

MHH

Mastech Digital Inc

N/A

Current Price

$6.34

Market Cap

78.2M

ML Signal

N/A

Logo Cardiff Oncology Inc.

CRDF

Cardiff Oncology Inc.

N/A

Current Price

$0.72

Market Cap

67.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MHH
CRDF
Founded
1986
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
78.2M
67.1M
IPO Year
2008
2012

Fundamental Metrics

Financial Performance
Metric
MHH
CRDF
Price
$6.34
$0.72
Analyst Decision
Buy
Analyst Count
0
6
Target Price
★ $12.75
$6.28
AVG Volume (30 Days)
7.0K
★ 346.5K
Earning Date
10-30-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 27.37
EPS
★ 0.01
N/A
Revenue
★ $191,371,000.00
$365,993.00
Revenue This Year
N/A
N/A
Revenue Next Year
$5.94
$5.62
P/E Ratio
$627.00
★ N/A
Revenue Growth
N/A
★ 49.61
52 Week Low
$5.50
$0.71
52 Week High
$8.37
$3.31

Technical Indicators

Market Signals
Indicator
MHH
CRDF
Relative Strength Index (RSI) 43.26 30.76
Support Level $6.24 N/A
Resistance Level $6.84 $1.13
Average True Range (ATR) 0.32 0.06
MACD 0.03 -0.00
Stochastic Oscillator 10.35 5.60

Price Performance

Historical Comparison
MHH
CRDF

About MHH Mastech Digital Inc

Mastech Digital Inc is a provider of Digital Transformation IT Services. The Company offers data & analytics solutions & IT staffing services for both digital & mainstream technologies. The Group has two segments. Its Data & Analytics Services segment delivers specialized data management, data engineering, customer experience consulting, data analytics & cloud services to customers globally. The IT Staffing Services segment combines technical expertise with business process experience to deliver a broad range of services in digital & mainstream technologies. The company derives a majority of its revenue from IT staffing services. Geographically, the majority of revenue is generated from the United States.

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients.

Share on Social Networks: